These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16709319)

  • 1. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost.
    Covert D; Robin AL
    Curr Med Res Opin; 2006 May; 22(5):971-6. PubMed ID: 16709319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
    Reardon G; Schwartz GF; Mozaffari E
    Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
    Gagliuso DJ; Wang RF; Mittag TW; Podos SM
    Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.
    Walt JG; Wilensky JT; Fiscella R; Chiang TH; Guckian A
    Clin Drug Investig; 2007; 27(12):819-25. PubMed ID: 18020539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-year treatment patterns among new initiators of topical prostaglandin analogs.
    Schmier JK; Covert DW; Robin AL
    Curr Med Res Opin; 2009 Apr; 25(4):851-8. PubMed ID: 19231912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
    Schwartz GF; Tan J; Kotak S
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
    Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
    Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
    Parrish RK; Palmberg P; Sheu WP;
    Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.
    Eisenberg DL; Toris CB; Camras CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S105-15. PubMed ID: 12204706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.
    Frenkel RE; Frenkel M; Toler A
    BMC Ophthalmol; 2007 Sep; 7():16. PubMed ID: 17900371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
    Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
    Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
    Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
    Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.
    Hommer A; Wickstrøm J; Friis MM; Steeds C; Thygesen J; Ferreras A; Gouws P; Buchholz P
    Curr Med Res Opin; 2008 Apr; 24(4):1057-63. PubMed ID: 18315942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monotherapy with lipid structural derivatives in glaucoma].
    Călugăru D; Călugăru M
    Oftalmologia; 2010; 54(2):30-43. PubMed ID: 20827909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
    Crichton AC; Vold S; Williams JM; Hollander DA
    Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prostaglandin wars.
    Kaufman PL
    Am J Ophthalmol; 2003 Oct; 136(4):727-8. PubMed ID: 14516814
    [No Abstract]   [Full Text] [Related]  

  • 18. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.
    Arcieri ES; Santana A; Rocha FN; Guapo GL; Costa VP
    Arch Ophthalmol; 2005 Feb; 123(2):186-92. PubMed ID: 15710814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of intraocular pressure reducing effects of three prostaglandin eyedrops in open-angle glaucoma].
    Huang HL; Sun XH; Xiao M
    Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):109-13. PubMed ID: 21426839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
    Li N; Chen XM; Zhou Y; Wei ML; Yao X
    Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.